Korro Bio (KRRO) 10% Owner LP Buys $295K of Stock
Key Points
- Lynx1 Capital Management increased its stake in Korro Bio to 1,624,789 shares, a 1.57% increase.
- Korro Bio shares recently traded around $12.02, which is about equal to the closing price on the trade date.
- Analysts maintain a 'strong buy' rating on Korro Bio, with a mean price target of $20.20.
Get Korro Bio text alerts
We text you when insiders, Congress, analysts or big funds move on $KRRO.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Korro Bio, Inc. alert may contain errors. Disclosures
On October 26, 2026, Lynx1 Capital Management LP bought 25,124 shares of Korro Bio, Inc. (KRRO) at an average price of $11.75 per share, for a total value of about $295,091. This transaction was reported in a Form 4 filing with the SEC.
Following this purchase, Lynx1's stake in Korro Bio grew to 1,624,789 shares, marking a 1.57% increase in their ownership. Lynx1 holds a significant position as a 10% owner of the company.
KRRO
Korro Bio, Inc.
Lynx1 Capital Management LP vs. the S&P 500
Hypothetical returns from Lynx1 Capital Management LP's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Korro Bio
Lynx1 Capital Management LP is not the only institution involved with Korro Bio. NEA Management Company, LLC holds 1,297,893 shares, while Venrock Adviser, LLC has 1,009,500 shares. Atlas Venture Life Science Advisors, LLC reduced its holdings by 174,201 shares, ending with 962,884 shares. Balyasny Asset Management LP also cut its position, decreasing its holdings by 88,303 shares to 951,783 shares.
Korro Bio, Inc. Stock Down 0.2%
Korro Bio shares recently traded around $12.02, which is about equal to the closing price on the trade date. The stock is currently above its 50-day moving average by about 5.6% and above its 200-day moving average by about 1.7%. However, it remains significantly below its 52-week high of $42.70, down about 71.9% from that level.
Recent Earnings
Korro Bio reported trailing twelve-month revenue of $2,382,000. The company has yet to turn a profit, with an EPS of -$9.88. The next earnings report is expected on November 12, 2026.
Insider Buying and Selling at Korro Bio, Inc.
There has been notable insider activity in Korro Bio recently. On June 16, 2026, Chief Operating Officer Todd Chappell sold 3,168 shares at an average price of $10.83. Formela Jean Francois sold several batches of shares in June, including a notable sale of 119,005 shares at $14.25 on June 23.
Analysts Set New Price Targets
Analysts have a positive outlook for Korro Bio. On October 6, 2026, HC Wainwright & Co. reiterated a 'Buy' rating with a price target of $15.00. The consensus among analysts is a strong buy rating, with a mean price target of $20.20 based on ten opinions.
About Korro Bio
Korro Bio, Inc. is a biopharmaceutical company based in Cambridge, MA. It focuses on developing genetic medicines that edit RNA to treat rare and prevalent diseases. Its lead product candidate, KRRO-121, aims to address hyperammonemia. The company uses its RNA editing platform to create new treatment options.
Bottom Line
Investors will want to keep an eye on Korro Bio's upcoming earnings report on November 12, 2026, along with any further insider trades and institutional activity. Lynx1's recent purchase reflects ongoing interest in the company's potential despite recent insider selling.
Related Filing Alerts
Source: Lynx1 Capital Management LP's Form 4 filing on $KRRO (Oct 26, 2026). Written by software, not financial advice. How we make alerts